文献速递肿瘤 PET/CT骨显像与常规 SPECT

多学科团队对前列腺癌分期PSMA PET不确定骨摄取的判读表现:与PROMISE标准比较

Multidisciplinary team interpretation performance for indeterminate bone uptake on PSMA PET during prostate cancer staging: Comparison with PROMISE criteria.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2026-01-28

本研究回顾性分析744例前列腺癌分期PSMA PET/CT,不确定骨摄取总体发生率为16.9%,18F-PSMA-1007达40%;其中95例经多学科团队(MDT)讨论并与PROMISE分类比较,两者一致率为87.3%,长期随访数据在全部分歧病例中支持MDT判读。

要点

  • 分期PSMA PET不确定骨摄取总体发生率16.9%,18F-PSMA-1007可达40%。
  • MDT与PROMISE分类判读一致率为87.3%,长期随访分歧病例均支持MDT。
  • 推荐PET报告者使用PROMISE算法,并建议MDT讨论解决所有模棱两可发现。

核心结论

  • PROMISE分类对不确定骨PSMA摄取具有高判读准确性,但需注意Gleason评分、所用示踪剂和解剖定位相关陷阱。

研究设计与样本

  • 回顾性分析744例分期PSMA PET/CT(140例18F-PSMA-1007,604例68Ga-PSMA-11),其中95例经MDT讨论并与PROMISE分类比较。

主要发现

  • 分期PSMA PET不确定骨摄取总体发生率为16.9%,18F-PSMA-1007扫描中达40%。
  • MDT与PROMISE判读一致率为87.3%。
  • MDT更倾向于将较低Gleason评分患者及使用18F-PSMA-1007扫描中的不确定骨摄取判为阴性。
  • 全部判读分歧病例的长期随访数据均支持MDT判读。

关键数值与推荐

  • 分期PSMA PET不确定骨摄取总体发生率16.9%。
  • 18F-PSMA-1007扫描不确定骨摄取发生率40%。
  • MDT与PROMISE分类判读一致率87.3%。

临床怎么用

  • PET报告者推荐使用PROMISE算法判读不确定骨PSMA摄取。
  • 判读时需注意Gleason评分、所用示踪剂和解剖定位相关的常见陷阱。
  • 建议通过MDT讨论解决所有模棱两可的发现。

局限性

  • 仅95例经MDT讨论的扫描纳入与PROMISE分类的比较分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To compare the performance of a multidisciplinary team (MDT) with the proposed standardized PROMISE classification system for indeterminate bone uptake on staging PSMA PET. METHODS: 744 staging PSMA PET/CT scans (140 18F-PSMA-1007 and 604 68Ga-PSMA-11 PET/CT) were retrospectively reviewed for the presence of indeterminate bone metastatic staging. 95 scans which were discussed at an MDT meeting were further analysed for the comparison with the PROMISE classification system. MDT interpretation of the bone staging was recorded as positive or negative, based on risk stratification, imaging review, and clinically suitable management options. Additional resources were occasionally used, such as bone biopsy, musculoskeletal MRI, or re-evaluation after initial androgen deprivation therapy. MDT and PROMISE classification were compared for agreement. Statistical assessment was made on any differences in age, PSA, T-stage, Gleason score, risk, SUVmax and tracer used between negative and positive patients in both methods. Discordant cases were correlated with follow up data. RESULTS: The overall incidence of indeterminate bone uptake in staging PSMA PET scans was 16.9%, reaching 40% for 18F-PSMA-1007. There was substantial agreement between MDT and PROMISE interpretation (87.3%). The MDT was more likely to interpret an indeterminate bone uptake as negative in patients with lower Gleason score and in scans where 18F-PSMA-1007 was used. The data from long-term follow up favoured the MDT interpretation in all the cases of disagreement. Examples of pitfalls in rib or thoracic spine foci of uptake are presented and recommendations for PET reporters and MDTs have been generated based on the results. CONCLUSION: PROMISE may interpret indeterminate bone PSMA uptake with high accuracy. Therefore, PET reporters are recommended to use the PROMISE algorithm, while being mindful of common pitfalls related to the Gleason score, tracer used and anatomical localisation of indeterminate bone findings. Additional discussion in an MDT meeting is recommended with a view to resolve all equivocal findings.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Priftakis D, Aziz F, Bin Essa N, et al. Multidisciplinary team interpretation performance for indeterminate bone uptake on PSMA PET during prostate cancer staging: Comparison with PROMISE criteria. Eur J Nucl Med Mol Imaging. 2026. PMID: 41593361. doi:10.1007/s00259-026-07763-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。